Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZDL28
|
|||
| Drug Name |
ALN-XDH
|
|||
| Drug Type |
RNA interference
|
|||
| Indication | Gout [ICD-11: FA25; ICD-10: M10] | Phase 1/2 | [1] | |
| Company |
Alnylam Pharmaceuticals Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Xanthine dehydrogenase/oxidase messenger RNA (XDH mRNA) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05256810) A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.